Lobeglitazone, A Peroxisome Proliferator-Activated Receptor-Gamma Agonist, Inhibits Papillary Thyroid Cancer Cell Migration and Invasion by Suppressing p38 MAPK Signaling Pathway

BACKGROUND: Peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligands have been widely shown to correlate with epithelial-mesenchymal transition (EMT) and cancer progression. Lobeglitazone (LGZ) is a novel ligand of PPAR-γ; and its role in EMT and metastasis in papillary thyroid carcinoma (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Jun-Qing, Han, Jeong-Sun, Ha, Jeonghoon, Baek, Han-Sang, Lim, Dong-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566138/
https://www.ncbi.nlm.nih.gov/pubmed/34645125
http://dx.doi.org/10.3803/EnM.2021.1155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566138/
https://www.ncbi.nlm.nih.gov/pubmed/34645125
http://dx.doi.org/10.3803/EnM.2021.1155

Ejemplares similares